According to reports from CNBC TV18, Strides Pharma Science Ltd announced that the United States Food and Drug Administration (USFDA) completed a routine current Good Manufacturing Practices (cGMP) inspection at the company's flagship facility in Bengaluru. The inspection was conducted from May 12, 2026, to May 20, 2026, and at the conclusion of the inspection, the USFDA issued a Form 483 with five observations. A Form 483 represents a list of observations made during the inspection and is issued by USFDA inspectors after completion, though it does not represent a final FDA determination regarding the facility's GMP compliance. As per CNBC TV18, the Form 483 essentially serves as an official heads-up from the FDA about possible rule violations, but it doesn't mean final judgment yet.
As reported by CNBC TV18, following the Form 483 issuance, the company is given 15 days to submit its response to the USFDA explaining what steps the company will take to resolve the observations made by the USFDA. The company has confirmed it will respond to the observations within the stipulated timeline prescribed by the regulator and will keep the stock exchanges informed of any further developments related to the matter. According to CNBC TV18, Strides Pharma Science has emphasized its commitment to addressing the regulatory concerns and maintaining transparency with stakeholders regarding the resolution process.
According to CNBC TV18, shares of Strides Pharma Science Ltd ended at ₹1,145.00, down by ₹8.65, or 0.75%, on the BSE following the announcement of the USFDA inspection results. The market reaction reflects investor concerns about the regulatory observations at the company's flagship manufacturing facility. As per CNBC TV18, the stock dipped slightly after the news of the inspection results, reflecting market sentiment about the potential impact of the regulatory observations on the company's operations.
As reported by CNBC TV18, Strides Pharma Science has confirmed that it will respond to the observations within the stipulated timeline prescribed by the regulator. The company has emphasized its commitment to addressing the regulatory concerns and maintaining transparency with stakeholders regarding the resolution process. The company's proactive approach includes keeping stock exchanges informed of any further developments related to the matter, demonstrating its commitment to regulatory compliance and stakeholder communication. According to the latest reports, the management has confirmed they will address the concerns noted in the report within the stipulated timeframe to ensure continued compliance with international quality and safety benchmarks.
